News Room
News Releases
Oct. 08, 2020 (PDF/169KB) Corporate
Sumitomo Chemical and Sumitomo Dainippon Pharma Announce Establishment and Inception of Operations of a Joint Venture Company for CDMO Business in the field of Regenerative Medicine and Cell Therapy
Oct. 08, 2020 (PDF/29KB) Corporate
Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals
Oct. 06, 2020 (PDF/275KB) Products
Sunovion Announces the Commercial Launch of KYNMOBI (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes
Sep. 30, 2020 (PDF/98KB) R&D
Myovant Sciences Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix in Advanced Prostate Cancer
Sep. 23, 2020 (PDF/98KB) Corporate
Sumitomo Dainippon Pharma Establishes a Subsidiary in Taiwan
Sep. 18, 2020 (PDF/542KB) Others
Sumitomo Dainippon Pharma and KDDI Announce Start of Initiatives to Create New Platform for Communication between MRs and HealthCare Professionals Using XR
Sep. 17, 2020 (PDF/80KB) Corporate
Sumitomo Dainippon Pharma Announces Change in Executive Officer
Sep. 04, 2020 (PDF/104KB) Finances
Sumitomo Dainippon Pharma Determines Issuance Conditions for Publicly Offered Hybrid Bonds (Subordinated Bonds)
Sep. 01, 2020 (PDF/123KB) Corporate
Sumitomo Dainippon Pharma Announces Organizational Realignment and Change in Executive Officer
Aug. 18, 2020 (PDF/46KB) R&D
Myovant Sciences Announces FDA Acceptance of New Drug Application for Once-Daily Relugolix Combination Tablet for Uterine Fibroids
Documents for Press
Nov. 01, 2019 (PDF/1,557KB) Corporate
Press Conference Presentation for Definitive Agreement for Strategic Alliance with Roivant Sciences
Oct. 28, 2019 (PDF/926KB) Finances
Press Conference Presentation for Q2 FY2019 (April 1 to September 30, 2019)
Dec. 02, 2013 (PDF/414KB) R&D
Presentation material of press conference (Healios and DSP: Alliance for Japanese market-iPS cell technology into practical use-)